{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Proportion of patients with VGPR to therapy within 24 cycles of therapy initiation. (VGPR is \\>90% reduction in serum IgM from baseline)","groups":[{"description":"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.\n\n* Ibrutinib will be administered at a predetermined dose, once daily for 28 days\n* TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)\n* Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2.\n\nIBRUTINIB: Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days\n\nVenetoclax: Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.","id":"OG000","title":"Ibrutinib and Venetoclax"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"The primary objective of VGPR within 24 cycles of therapy was assessed starting at Cycle 3 Day 1 through the End of Treatment visit, range of 2 to 21 months after the initiation of therapy.","title":"Number of Participants With Very Good Partial Response Within 24 Cycles of Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}